DDInter1291 DDInter1676
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Nifedipine {u} (Compound) resembles {v} (Compound) Isradipine
Nifedipine {u} (Compound) resembles {v} (Compound) Nicardipine
Nifedipine {u} (Compound) treats {v} (Disease) hypertension
Nifedipine {u} (Compound) binds {v} (Gene) CALM1
Nifedipine {u} (Compound) upregulates {v} (Gene) MTHFD2
Nifedipine {u} (Compound) palliates {v} (Disease) systemic scleroderma
Nifedipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Nifedipine {u} (Compound) downregulates {v} (Gene) FOXO4
Nifedipine {u} (Compound) causes {v} (Side Effect) Sleep disorder
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Nifedipine (Compound) resembles Isradipine (Compound)
Nifedipine (Compound) resembles Nicardipine (Compound)
Nifedipine (Compound) treats hypertension (Disease)
Nifedipine (Compound) binds CALM1 (Gene)
Nifedipine (Compound) upregulates MTHFD2 (Gene)
Nifedipine (Compound) palliates systemic scleroderma (Disease)
Nifedipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Nifedipine (Compound) downregulates FOXO4 (Gene)
Nifedipine (Compound) causes Sleep disorder (Side Effect)
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide